Loading…
Purple Biotech Ltd is projected to rise to $1.97 by 2027, a +26% move from its current price of $1.56. PPBT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $1.49 | $1.56 | $1.63 | +0.05% |
| Jul 15 | $1.46 | $1.56 | $1.66 | +0.11% |
| Jul 16 | $1.44 | $1.56 | $1.69 | +0.16% |
| Jul 17 | $1.42 | $1.56 | $1.71 | +0.22% |
| Jul 18 | $1.41 | $1.56 | $1.73 | +0.27% |
| Jul 19 | $1.39 | $1.56 | $1.75 | +0.32% |
| Jul 20 | $1.38 | $1.56 | $1.76 | +0.38% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.38 | $1.56 | $1.76 | +0.38% |
| Week 2 | $1.32 | $1.57 | $1.86 | +0.76% |
| Week 3 | $1.27 | $1.57 | $1.95 | +1.14% |
| Week 4 | $1.23 | $1.58 | $2.02 | +1.52% |
| Week 5 | $1.20 | $1.58 | $2.09 | +1.91% |
| Week 6 | $1.18 | $1.59 | $2.15 | +2.29% |
| Week 7 | $1.15 | $1.60 | $2.21 | +2.68% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. The company is in the healthcare sector.
Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.
The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020.
The company was incorporated in 1968 and is headquartered in Rehovot, Israel.
Purple Biotech Ltd (PPBT) is a healthcare stock currently priced at $1.56 with a market cap of $1.45M and a market rank of 5493.
The near term forecast shows 2026 values around the current price with min $1.54, avg $1.56, max $2.18 and ROI 0, sentiment Neutral. The 2027 forecast moves higher to an avg of $1.97 with ROI 26.4 and a bullish tilt, followed by 2028 avg $2.11 with ROI 35.5 and a bullish tilt, then 2029 avg $1.94 with ROI 24.5 and bullish sentiment.
Longer horizon outlook progresses to 2030 with avg $1.73 and ROI 10.9 (neutral), then 2040 with avg $3.23 and ROI 107.9 (bullish), and 2050 with avg $4.63 and ROI 197.7 (bullish).
A major floor 67.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.0% away) — a key level to hold.
The nearest ceiling, 98.7% above — a clean break opens room to run.
A major ceiling 222.8% above — clearing it would confirm fresh momentum.
Key PPBT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PPBT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.62 | Sell | $1.61 | Sell |
| MA 10 | $1.66 | Sell | $1.67 | Sell |
| MA 20 | $1.68 | Sell | $1.87 | Sell |
| MA 50 | $2.75 | Sell | $2.60 | Sell |
| MA 100 | $3.59 | Sell | $3.77 | Sell |
| MA 200 | $5.25 | Sell | $8.06 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 30.72 | Neutral |
| Stoch RSI (14) | 60.58 | Neutral |
| CCI (20) | -132.79 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | -12.15 | Sell |
| Bollinger %B (20,2) | 0.08 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -2.24 | Sell |
| Awesome (5,34) | -0.58 | Sell |
| Ultimate (7,14,28) | 35.72 | Neutral |
| Momentum (10) | -0.20 | Sell |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 1.56 | Sell |
| ADX (14) | 36.89 | Sell |
| ATR (14) | 0.10 | Info |
Near-term sentiment is Neutral with RSI14 at 30. The price is below both the 50-day and 200-day moving averages, with the SMA50 at $2.75 and the SMA200 at $5.25. A near-term support level sits at $1.54 and a near-term resistance at $3.09.
The stock has traded within the 30-day range of $1.15 to $2.11, indicating a contained short-term price path around the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.54 | $1.56 | $2.18 | 0% | Neutral | |
| $1.46 | $1.97 | $2.85 | +26% | Bullish | |
| $1.49 | $2.11 | $3.23 | +36% | Bullish | |
| $1.31 | $1.94 | $3.10 | +24% | Bullish | |
| $1.12 | $1.73 | $2.86 | +11% | Neutral | |
| $1.10 | $1.75 | $3.00 | +13% | Neutral | |
| $1.06 | $1.75 | $3.09 | +13% | Neutral | |
| $1.33 | $2.26 | $4.09 | +46% | Bullish | |
| $1.45 | $2.56 | $4.73 | +64% | Bullish | |
| $1.32 | $2.39 | $4.51 | +54% | Bullish | |
| $1.54 | $3.23 | $6.66 | +108% | Bullish | |
| $2.08 | $4.63 | $10.65 | +198% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.54 | $1.56 | $1.88 | +0.00% |
| August 2026 | $1.27 | $1.53 | $1.91 | -1.46% |
| September 2026 | $1.34 | $1.63 | $2.08 | +6.61% |
| October 2026 | $1.38 | $1.70 | $2.19 | +3.91% |
| November 2026 | $1.31 | $1.63 | $2.13 | -3.92% |
| December 2026 | $1.31 | $1.65 | $2.18 | +0.91% |
Click any year to see its month-by-month PPBT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, PPBT is projected to trade between $1.54 and $2.18, averaging $1.56 — a potential gain of 0% from today's $1.56. A consolidation phase looks the most probable path here.
Purple Biotech Ltd's 2027 outlook centres on $1.97, within a $1.46 to $2.85 range. That is up +26% on the projected 2026 average. That marks a +26% change versus current levels. Momentum favours further upside here.
By 2028, PPBT could reach as high as $3.23, with a base case around $2.11 and support toward $1.49 — roughly +36% from $1.56. Buyers look set to stay in control over this stretch.
Expect PPBT to range from $1.31 to $3.10 through 2029. The $1.94 average target implies a +24% move from current prices. That is -8% versus the projected 2028 average. Momentum favours further upside here.
The PPBT price prediction for 2030 points to an average of $1.73 (low $1.12, high $2.86) — a potential gain of +11% on today's $1.56. A consolidation phase looks the most probable path here.
In 2031, PPBT is projected to trade between $1.10 and $3.00, averaging $1.75 — a potential gain of +13% from today's $1.56. That is up +1% on the projected 2030 average. Price action looks broadly range-bound.
Purple Biotech Ltd's 2032 outlook centres on $1.75, within a $1.06 to $3.09 range. That is up 0% on the projected 2031 average. That marks a +13% change versus current levels. A consolidation phase looks the most probable path here.
By 2033, PPBT could reach as high as $4.09, with a base case around $2.26 and support toward $1.33 — roughly +46% from $1.56. Momentum favours further upside here.
Expect PPBT to range from $1.45 to $4.73 through 2034. The $2.56 average target implies a +64% move from current prices. That is up +13% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The PPBT price prediction for 2035 points to an average of $2.39 (low $1.32, high $4.51) — a potential gain of +54% on today's $1.56. Momentum favours further upside here.
In 2040, PPBT is projected to trade between $1.54 and $6.66, averaging $3.23 — a potential gain of +108% from today's $1.56. That is up +35% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Purple Biotech Ltd's 2050 outlook centres on $4.63, within a $2.08 to $10.65 range. That is up +43% on the projected 2040 average. That marks a +198% change versus current levels. Momentum favours further upside here.
Investing $1,000 in PPBT today (≈ 643.086817 PPBT) could be worth
$2,976.48
+$1,976.48 (+198%) by 2050 · US Dollar
Based on the average projected PPBT price of $4.63 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PPBTwould be worth at today's price.
$1,000 invested in PPBT on Jul 10, 2025 (≈ 39.682538 PPBT) would be worth
$61.71
-$938.29 (-93.8%) today · 0.06× · US Dollar
Based on a PPBT entry price of $25.2 vs. today's $1.56.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.7 | $914.71 | -8.5% |
| 1 month ago | $2.96 | $525.34 | -47.5% |
| 3 months ago | $4.13 | $376.51 | -62.3% |
| 6 months ago | $6.8 | $228.68 | -77.1% |
| 1 year ago | $25.2 | $61.71 | -93.8% |
| All time (5.0y) ago | $892 | $1.74 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PPBT forecast.
Our base-case forecast reaches $3.10 around 2040.
Implied market cap at $3.10: $2.89M
The multi-year forecast shows upside potential across the horizon. In 2030 the avg is $1.73 with ROI of 10.9% and neutral sentiment, while the later years begin to show larger gains, with 2040 avg at $3.23 and ROI 107.9% and 2050 avg at $4.63 and ROI 197.7% as bullish. The progression from 2027 through 2029 remains bullish with avg values of $1.97, $2.11, and $1.94 respectively and ROI values of 26.4%, 35.5%, and 24.5%.
These figures illustrate a path of extended upside but also emphasize the risk given the early-stage pipeline and high volatility (annualized volatility 90%).
Tap a question to reveal the answer.
2030 forecast shows min $1.12, avg $1.73, max $2.86 with ROI 10.9% and sentiment Neutral.
Forecasts show positive upside in several years with ROI values such as 26.4% (2027), 35.5% (2028), 24.5% (2029), 45.6% (2033), 64.4% (2034), 53.6% (2035), 107.9% (2040), and 197.7% (2050). However, 2026 yields ROI 0 and the stock carries high volatility (90%), so outcomes are uncertain.
Yes, the max values show $3.23 in 2028, $4.09 in 2033, $6.66 in 2040, and $10.65 in 2050.
Current price is $1.56 and market cap is $1.45M.
Near-term sentiment is Neutral with RSI14 at 30. The 50-day moving average is $2.75 and the 200-day moving average is $5.25. Support is at $1.54 and resistance at $3.09, with a 30-day trading range from $1.15 to $2.11.
Purple Biotech Ltd Community Discussion
0Share your Purple Biotech Ltd price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.